NCT03193775View on ClinicalTrials.gov

Impact of Hepatitis B Vaccination on HBs Antigenemia

NACompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

August 1, 2011

Primary Completion Date

October 1, 2015

Study Completion Date

October 1, 2015

Conditions
HBV
Interventions
BIOLOGICAL

HBV vaccine

HBV vaccine which contains Purified HBsAg produced by recombinant DNA technology (Euvax-B, LG Life sciences, Korea) intramuscularly in deltoid region at three different time intervals (0, 1, 6 months).

All Listed Sponsors
lead

Zagazig University

OTHER_GOV

NCT03193775 - Impact of Hepatitis B Vaccination on HBs Antigenemia | Biotech Hunter | Biotech Hunter